Görüntüleme
42
Malign melanom, metastatik evrede standart kemoterapi rejimlerine dirençli agresif seyirli bir kanser türüdür. MAP kinaz sinyal yolağının melanom gelişimindeki rolünün keşfinden sonra kullanılmaya başlanan BRAF-MEK inhibitörleri ile metastatik melanomun tedavisinde yeni bir döneme girilmiştir. Ancak bu ilaçların kullanımı sırasında doz redüksiyonu, ilaca ara verme ve ilaç kesilmesine kadar gidebilen bir takım yan etkiler gözlenebilir. İlaç ilişkili yan etkiler, hastaların tedaviden optimal şekilde yararlanabilmeleri için hızlı bir yaklaşım ve yönetim gerektirir. Bu olgu sunumu ve kısa derlemede, BRAF-MEK inhibitörü kombinasyonu ile birinde ilaç ateşi, pnömonit, nodüler eritematöz döküntü diğerinde ise ilaç ateşi, lökopeni, nötropeni gelişen iki metastatik melanom olgusu ve gelişen yan etkilerin yönetimine yönelik klinik yaklaşım özetlendi.
Malignant melanoma is a type of aggressive populated cancer that is resistant to standard chemotherapy regimes in the metastatic stage. With the BRAF-MEK inhibitors, which began to be used after the discovery of the role of the MAP kinase signal pathway in the development of melanoma, a new period in the treatment of metastatic melanoma has entered. However, a number of side effects can be observed during the use of these medications, which can go to dose reduction, medication interruption and medication interruption. The medication-related side effects require a quick approach and management so that patients can benefit optimally from the treatment. The presentation of this phenomenon and in a short summary, BRAF-MEK inhibitors combined with a drug fever, pneumonitis, nodular erythematosus erythema in the other, and the clinical approach to the management of the two metastatic melanoma phenomena developing drug fever, locopene, neutropene and developing side effects was summarized.
Malignant melanoma is an aggressive cancer type resistant to standart chemotherapy regimens in the metastatic stage. A new era has begun in the treatment of metastatic melanoma with BRAF-MEK inhibitors, which were used after the discovery of the MAP kinase signal pathway in the development of melanoma. However during the use of these drugs, a number of side effects can be observed, resulting with dose reduction and interruption or discontinuation. Drug-related side effects require a quick approach and management so that patients can benefit optimally from treatment. In this report, two patients with metastatic melanoma were evaluated, of whom one of them with pyrexia, pneumonitis noduler erythematous eruption and the other with neutropenia/ leukopenia and pyrexia due to BRAF-MEK inhibitors and clinical management of these side effects were reviewed.
Alan : Sağlık Bilimleri
Dergi Türü : Uluslararası
Makale Detay 
Benzer Makaleler
PDF Görüntüle
Dergi Bilgisi
Eseri Dinleyin
Alıntı Yap
Bu Sayfayı Yazdırın
Paylaş
Mendeley
